Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Media Kit
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
|
My Humble Opinion
|
Other People's Opinion
|
|
A "Must Read" Blog for Insiders. -- Wall Street Journal
|
A bi-weekly podcast. Listen and call-in live online or download to your iPod!
|
Marketing & Sales Guidelines, Regulations, Laws
| Return to All Pharma Marketing Blog Topics |
The following Pharma Marketing Blog topics focus on guidelines, regaulations, and laws applicable to the pharmaceutical marketing and sales.
If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
Posts are listed in reverse chronological order:
- Pharma's New Marketing Partner: Medical Journals
- FTC, Generics, and the War in Iraq
- FDA Won't be Previewing TV DTC Ads!
- Did Pfizer Run a Chantix "Bookend" Ad During 60 Minutes?
- Mevacor - STRIKE THREE! Yer Outta Here!
- Lilly, Sweden, Bribes and Conspiracy Theories
- The "One-Click Rule": Rant or No Rant?
- The Natrecor Waterboard Tortured Tchotchke
- What the US FDA Could Learn from China's FDA
- J&J Blog, Shire PR: The Whole Story and Nothing But the Whole Story!
- Pfizer Facebook a la Sermo?
- Regulating DTC for BTC
- Lilly Cymbalta Marketers are NOT Practicing What Lilly Executives Preach!
- DTC Here to Stay; Pet Turtles Too!
- Web 2.0 Pharma Marketing Tricks for Dummies
- FDA at a Mall Near You: The Manchurian Connection
- Rozerem's Cheapskate Sweepstakes Violates Children's Online Privacy Protection Act
- State Sponsored Pharma Ads: It Could Happen!
- FDA's Chang and Eng: Benefit vs. Risk
- Marketing's New Maxim: At Least Do No Harm!
- Google's "Old School" Health Advisory Council
- AZ: No Cupcakes for You!
- On Cupcakes and HIPAA
- Temple vs. Nissen: Blood Rematch
- Imagine There's No DTC. I Wonder If You Can.
- Physician Empathy vs. Pre-Launch Marketing
- Americans Skeptical Of Pharma Cause Marketing
- 'Round the Sphere: You're Fired!
- Group of 7 (code name "whiskey") Reports Unethical AZ Behavior to OIG
- The Zubillaga Affair: Effect on the Prospects for Pharma Blogging
- Botox Banality Not a Boon for TV Sitcoms
- Web 2.0 Hates Sally
- Device DTC: Imagine How Far It Will Go!
- Tilting Again at the PhRMA Windmill
- Takeda: It Isn't a Reminder Ad --- Wha!!!
- Prilosec OTC Bunco Artists
- Rozerem Reverts to Reminder TV Ads
- Revolution Health and the Wisdom of Crowds
- Nice Try, Daiichi!
- Introducing...the All-Pharma Lobbying Lineup!
- Brave New Pharma?
- If FDA were as Powerful as FTC
- The Next Blockbuster - You Decide!
- Celebrex Joins the bAdWord Bandwagon!
- Off-Label Confusion
- Lame-Duck Senate Roasts Eschenbach Turkey!
- Wooing Dems: Thank You Mr. Kindler!
- What's In Store from Congress?
- The "Girl from Google"
- Clear Words, Obscure Benefits
- Lunesta, Google, and "bAdWords"
- Rozerem Sleeper Cell at Pri-Med Conference
- WLF: A No-Risk Ad is a Good Ad
- FDA Paralyzed: Who Will Protect Us?
- Licensing Sales Reps: Is It a Bad Idea?
- Off-label Marketing: Next State Issue
- Gifts That Keep on Giving
- DTC Regulation: Trick or Treat?
- New Assault on Pharma Marketing?
- Ethical Pharma Marketing: Oxymoronic?
- PhRMA Finalizes DTC Principles
- Restrict DTC, but Extend the Patent for New Drugs
- To Ban or Not to Ban DTC, That is the Question
- WLF Watches FDA Watching Drug Ads
- New DTC Principles Emerging
- Proposal for a Drug Risk Advisory System
- FDA Drug Watch Site Guidelines
- Separation of Church and State
- "Bioshield" Boondoggle
- Buzz is NOT regulated by FDA
|